EyePoint Pharmaceuticals (EYPT) Prices 9.1M Share Common Offering at $11/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Nasdaq futures fall as oil prices jump, key earnings loom
- Brent hits five-month high as attacks on ships, Saudi sites fuel supply worries
- Loop Capital downgrades Apple, sees no recovery of cut iPhone shipments
- Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish
- ByteDance, Alibaba and Tencent order $35 billion of Nvidia chips: Reuters
- Cerebras Systems falls as TD Cowen cuts price target
- Nasdaq climbs as chip and AI-linked stocks bounce back
- 3M issues warrant to Amazon in $6B data center product deal
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
- Flutter Entertainment to cut up to 1,400 jobs amid UK tax increases
EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
February 1, 2021 10:17 PM ESTWATERTOWN, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds of the offering to the Company are expected to be $100.1 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, EyePoint granted the underwriters a thirty-day option to... More



